1 week Ago By ABMN Staff
Blue Bell Private Wealth Management LLC cut its position in shares of AbbVie Inc. ( NYSE:ABBV – Free Report ) by 32.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.
The firm owned 197 shares of the company’s stock after selling 95 shares during the quarter. Blue Bell Private Wealth Management LLC’s holdings in AbbVie were worth $34,000 at the end of the most recent reporting period. Other hedge funds have also bought and sold shares of the company.
American National Bank increased its holdings in AbbVie by 4.8% in the fourth quarter. American National Bank now owns 59,392 shares of the company’s stock worth $9,204,000 after purchasing an additional 2,695 shares in the last quarter.
AXS Investments LLC boosted its stake in AbbVie by 3.3% during the fourth quarter. AXS Investments LLC now owns 9,530 shares of the company’s stock worth $1,477,000 after acquiring an additional 307 shares in the last quarter.
Mizuho Markets Americas LLC grew its holdings in AbbVie by 33.4% in the fourth quarter. Mizuho Markets Americas LLC now owns 30,914 shares of the company’s stock worth $4,791,000 after purchasing an additional 7,737 shares during the period.
West Coast Financial LLC increased its stake in AbbVie by 9.7% in the first quarter. West Coast Financial LLC now owns 1,578 shares of the company’s stock valued at $287,000 after purchasing an additional 140 shares in the last quarter.
Finally, FCG Investment Co acquired a new position in shares of AbbVie during the first quarter valued at about $1,413,000. Institutional investors own 70.23% of the company’s stock.
AbbVie Stock Up 0.3 % AbbVie stock opened at $193.52 on Friday.
AbbVie Inc. has a fifty-two week low of $135.85 and a fifty-two week high of $199.
95. The company has a debt-to-equity ratio of 8.51, a quick ratio of 0.
71 and a current ratio of 0.81. The firm’s 50-day simple moving average is $183.
88 and its 200 day simple moving average is $174.61. The stock has a market cap of $341.
73 billion, a PE ratio of 57.42, a price-to-earnings-growth ratio of 2.68 and a beta of 0.
64. AbbVie Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be issued a dividend of $1.
55 per share. This represents a $6.20 annualized dividend and a yield of 3.
20%. AbbVie’s dividend payout ratio (DPR) is presently 183.98%.
Insiders Place Their Bets In related news, Chairman Richard A. Gonzalez sold 282,845 shares of the company’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $175.
00, for a total transaction of $49,497,875.00. Following the sale, the chairman now directly owns 513,099 shares in the company, valued at approximately $89,792,325.
The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link . In related news, Chairman Richard A. Gonzalez sold 66,500 shares of the stock in a transaction dated Monday, August 5th.
The stock was sold at an average price of $186.52, for a total transaction of $12,403,580.00.
Following the sale, the chairman now owns 446,599 shares of the company’s stock, valued at approximately $83,299,645.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website .
Also, Chairman Richard A. Gonzalez sold 282,845 shares of AbbVie stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $175.
00, for a total value of $49,497,875.00. Following the transaction, the chairman now directly owns 513,099 shares of the company’s stock, valued at approximately $89,792,325.
The disclosure for this sale can be found here . Company insiders own 0.25% of the company’s stock.
Wall Street Analyst Weigh In Several analysts have recently commented on the company. Piper Sandler Companies restated an “overweight” rating and issued a $190.00 target price on shares of AbbVie in a research note on Wednesday, July 3rd.
Barclays raised their price objective on AbbVie from $187.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, July 26th.
William Blair raised AbbVie to a “strong-buy” rating in a research report on Friday, August 30th. Morgan Stanley increased their target price on AbbVie from $211.00 to $218.
00 and gave the stock an “overweight” rating in a report on Monday, August 12th. Finally, HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a research note on Wednesday, June 5th.
Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, AbbVie currently has a consensus rating of “Buy” and an average price target of $191.64.
Get Our Latest Research Report on AbbVie About AbbVie ( Free Report ) AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. Read More Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.
com's FREE daily email newsletter ..
